Goff D C, Renshaw P F, Sarid-Segal O, Dreyfuss D A, Amico E T, Ciraulo D A
Freedom Trail Clinic, Erich Lindemann Mental Health Center, Boston, MA 02114.
Biol Psychiatry. 1993 May 15;33(10):700-6. doi: 10.1016/0006-3223(93)90119-x.
The goal of this study was to determine whether selegiline (L-deprenyl), a selective monoamine oxidase B inhibitor and antioxidant, would improve neuroleptic-induced tardive dyskinesia (TD). Thirty-three patients with TD were randomly assigned to selegiline 10 mg/day or placebo for 6 weeks and were assessed at baseline and at weeks 1, 2, 4, and 6 for TD, parkinsonism, akathisia, depression, and positive and negative symptoms. Examinations for TD were videotaped and scored by a rater unaware of the temporal sequence of examination. Twenty-eight subjects completed at least 1 week of treatment; all five dropouts were receiving selegiline. When baseline score and gender were controlled, the group receiving selegiline displayed significantly less improvement of TD compared with the placebo group. The two treatment groups did not differ in any other outcome measure. Selegiline was less effective than placebo in reducing symptoms of TD over a 6-week trial. This may be the result of the dopamine agonist effects associated with selegiline.
本研究的目的是确定司来吉兰（L-司立吉林），一种选择性单胺氧化酶B抑制剂及抗氧化剂，是否能改善抗精神病药物所致的迟发性运动障碍（TD）。33例TD患者被随机分配至接受每日10mg司来吉兰或安慰剂治疗6周，并在基线期以及第1、2、4和6周时对TD、帕金森症、静坐不能、抑郁以及阳性和阴性症状进行评估。对TD的检查进行录像，并由一名不知检查时间顺序的评估者评分。28名受试者完成了至少1周的治疗；所有5名退出者均接受司来吉兰治疗。在对基线评分和性别进行控制后，与安慰剂组相比，接受司来吉兰治疗的组在TD改善方面显著较少。两个治疗组在任何其他结局指标上均无差异。在为期6周的试验中，司来吉兰在减轻TD症状方面比安慰剂效果更差。这可能是与司来吉兰相关的多巴胺激动剂效应的结果。
